1192 Approval of drugs which may be used by certain optometrists

DEPARTMENT OF HEALTH

Approval of Drugs Which May Be Used by Certain Optometrists

[41 Pa.B. 3941]
[Saturday, July 16, 2011]

 Under the Optometric Practice and Licensure Act (act) (63 P. S. §§ 244.1—244.12), and specifically as the act was amended by the act of December 16, 2002 (P. L. 1950, No. 225) (Act 225), the Secretary of Health (Secretary) has the authority to approve drugs for use in the practice of optometry as the ''practice of optometry'' is defined in Act 225. The State Board of Optometry resubmitted a request to the Secretary by letter received on June 2, 2011, and requested that the Secretary approve the use of the following drug. Act 225 requires that the Secretary, within 90 days of the receipt of the list of drugs, and in consultation with the Physician General, approve or disapprove for good cause each drug. The Secretary has found good cause to approve the use of the following drug in the practice of optometry:

 alcaftadine ophthalmic solution 0.25%.

 The approval of the use of this drug is effective upon publication of this notice in the Pennsylvania Bulletin.

 Persons with a disability who require an alternative format of this notice (for example, large print, audiotape or Braille) should contact the Bureau of Community Program Licensure and Certification, 132 Kline Plaza, Suite A, Harrisburg, PA 17104, [phone], for speech and/or hearing impaired persons V/TT [phone], or the Pennsylvania AT&T Relay Services at [phone] (TT).

ELI N. AVILA, MD, JD, MPH, FCLM, 
Secretary

[Pa.B. Doc. No. 11-1192. Filed for public inspection July 15, 2011, 9:00 a.m.]